BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25862872)

  • 41. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
    Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
    Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma.
    Kamiyama T; Takahashi M; Nakagawa T; Nakanishi K; Kamachi H; Suzuki T; Shimamura T; Taniguchi M; Ozaki M; Matsushita M; Furukawa H; Todo S
    Ann Surg; 2006 Sep; 244(3):451-63. PubMed ID: 16926571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes of serum alpha-fetoprotein and alpha-fetoprotein-L3 after hepatectomy for hepatocellular carcinoma: prognostic significance.
    Zhang XF; Yin ZF; Wang K; Zhang ZQ; Qian HH; Shi LH
    Hepatobiliary Pancreat Dis Int; 2012 Dec; 11(6):618-23. PubMed ID: 23232633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
    Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
    Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy].
    Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY; Hu WY; Han B
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):753-8. PubMed ID: 23291069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.
    Oda K; Ido A; Tamai T; Matsushita M; Kumagai K; Mawatari S; Saishoji A; Kure T; Ohno K; Toyokura E; Imanaka D; Moriuchi A; Uto H; Oketani M; Hashiguchi T; Tsubouchi H
    Oncol Rep; 2011 Nov; 26(5):1227-33. PubMed ID: 21874252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
    Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
    Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
    Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
    Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3.
    Okuda H; Saito A; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2005 May; 20(5):759-64. PubMed ID: 15853991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.
    Song BC; Suh DJ; Yang SH; Lee HC; Chung YH; Sung KB; Lee YS
    J Clin Gastroenterol; 2002; 35(5):398-402. PubMed ID: 12394228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.
    Hsu CY; Huang YH; Hsia CY; Su CW; Lin HC; Loong CC; Chiou YY; Chiang JH; Lee PC; Huo TI; Lee SD
    J Hepatol; 2010 Jul; 53(1):108-17. PubMed ID: 20451283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
    Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N
    Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
    Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
    Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melanoma antigen-1 mRNA combined with alpha-fetoprotein mRNA levels in peripheral blood of patients with hepatocellular carcinoma: a predictor of postoperative recurrence or metastasis?
    Zhang Y; Song T; Meng L; Wu X; Ba Y; Li Q
    ANZ J Surg; 2009; 79(1-2):62-9. PubMed ID: 19183381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
    Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
    Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
    Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma.
    Shim JH; Han S; Lee YJ; Lee SG; Kim KM; Lim YS; Chung YH; Lee YS; Lee HC
    Ann Surg; 2013 Apr; 257(4):708-17. PubMed ID: 23108121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.